RemeGen Ltd.

RemeGen’s telitacicept, the world’s first approved fusion protein targeting B-cell lymphocyte stimulator/a proliferation inducing ligand (BLyS/APRIL), is looking increasingly likely to provide a stron

Despite struggling with the financial burden, Chinese firm RemeGen is pulling out all the stops for its ongoing global Phase III RemeMG study to repeat the positive safety and efficacy outcomes from

Throughout 2024 and against persistent financial headwinds, novice and returning sole Chinese company sponsors of clinical trials initiated a total of seven new global Phase III programs that included

Many of China’s homegrown first-in-class drugs have had a hard time becoming rainmakers for their originators, with few becoming blockbusters in domestic or international sales terms. Since the first